Apoptosis - Global Strategic Business Report

Description: This report analyzes the worldwide markets for Apoptosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets.


Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

Contents: APOPTOSIS
A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
   Study Reliability and Reporting Limitations 1
   Disclaimers 2
   Data Interpretation & Reporting Level 3
   Quantitative Techniques & Analytics 3
   Product Definitions and Scope of Study 3

2. INDUSTRY OVERVIEW 4
   Apoptosis: A Natural Part of Cell Lifecycle 4
   The Cell Death Pathway: A Review 4
   Apoptosis Modulating Drugs All Set for Commercial Stage Competition 5
   Table 1: Apoptosis Drugs Pipeline Scenario Worldwide (2008): Percentage Share Breakdown of Number of Apoptosis Modulating Drugs in Development by Development Stage (includes corresponding Graph/Chart) 6
   R&D Scenario 6
   Table 2: Apoptosis R&D Scenario Worldwide (2010): Percentage Share Breakdown of Number of Apoptosis Modulating Drugs in Development by Treatment Area (includes corresponding Graph/Chart) 7

   Table 3: Apoptosis Drug Development Worldwide (2010): Percentage Share Breakdown of Number of Apoptosis Modulating Drugs in Development by Agent Type (includes corresponding Graph/Chart) 7
Table 4: Top Nations for Apoptosis Research (2011):
Breakdown of Number of Researchers Involved in Apoptosis
Research by Country (includes corresponding Graph/Chart) 8
Popular Classes of Molecules Influencing the Apoptotic
Process: A Review 8
Noteworthy Molecular Targets for Apoptosis 8
Death Receptors 8
Caspases 9
IAPs and SMAC 9
Bcl-2 proteins 9
p53 9
Table 5: Apoptosis Drugs Pipeline Worldwide (2010):
Percentage Share Breakdown of Number of Apoptosis
Modulating Agents in Development by Molecular Target 9
HSP90: A Popular Gene Target for Apoptosis 10
Apoptosis: The Key to Cutting Edge Cancer Treatment/Therapies 10
Table 6: Apoptosis R&D in Cancer Treatment (2010):
Percentage Share Breakdown of Number of Apoptosis Modulating
Drugs in Development by Type of Cancer (includes
corresponding Graph/Chart) 11
Focus on Targeted Therapy Bodes Well for Apoptosis-Targeted
Therapies for Cancer 11
Overcoming Therapy/Drug Resistance: A Major Business Case for
Direct Apoptogens 12
Factors Encouraging Investments in Apoptosis Based Cancer Drugs 12
Rise in Cancer Incidences Fosters Growth in Cancer Related
Apoptosis Research 12
Low Entry Barriers in Cancer Research Encourages Cancer
Related Apoptosis Research 13
Government Funded Investments Bode Well for Cancer Related
Apoptosis Research 13
High Prices/Efficacy Encourage Pharmas in Pushing
Commercialization of Apoptosis-Based Anticancer Drugs 14
Kinase inhibitors: Cutting Edge Second Generation of Indirect
Apoptogens 14
Table 7: World Market for Kinase Inhibitors (2010):
Breakdown of Sales (in US$ Million) of Key Kinase Inhibitor
Drugs (includes corresponding Graph/Chart) 15
Outlook 15

3. APOPTOSIS: A CONCEPTUAL OVERVIEW 16
Apoptosis: Definition 16
Importance of Apoptosis 16
Apoptosis Mechanism 17
Execution of Apoptosis 17
Dead Cell Removal 18
Apoptosis & Diseases 18
Faulty Apoptotic Pathways 18
Cancer 18
Non-Cancer Diseases 18
Neurodegeneration 19
Liver Diseases 19
Heart Diseases 19
Autoimmune Diseases 19
Categories of Apoptogens in the Marketplace 20
First Generation Indirect Apoptogens (IAs) 20
Second Generation Indirect Apoptogens (IAs) 20
Direct Apoptogens 20
How Apoptosis is Targeted in Disease Research 20
Role of Death Receptors in Apoptosis 21
TNF Receptor Signaling 21
Signaling by Fas (CD95) 21
Apoptosis Induction by TRAIL 22
Caspase Inhibitors & Activators 22
Role of Intrinsic (Mitochondrial) Death Pathways in Apoptosis 22
Bcl-2 Family Proteins 23
Targeting Mitochondria Directly 23
Role of IAPs (inhibitors of apoptosis proteins) in Apoptosis Regulation 23
Tumor Suppressor p53 24

4. DRUG APPROVALS, INTRODUCTIONS AND CLINICAL TRIALS 25
Cleveland BioLabs Pre-Clinical Data Demonstrates Anticancer Effect of CBLB502 25
Senesco Technologies Files for IND for SNS01-T 25
Celgene Corporation Receives FDA approval for Priority Review of sNDA for ISTODAX® 25
IntelliCyt Introduces a Suite of Assay Kits for Apoptosis Screening 25
Vitamin E Tocotrienol Found to Increase Cancer Cell Apoptosis Without Toxicity 26
Protectan Technology May Lead to Drugs That Mitigate Effects of Radiation Exposure 26
VisEn Partners with MosaMedix to Introduce Annexin-Vivo 750 Imaging Agent for Monitoring Programmed Cell Death 26
AnaSpec Introduces Z-Fish Antibodies 27
Rexahn Pharmaceuticals Publishes Preclinical Research Data of Quinoxaliny1-Piperazine Compounds 27
Aegera Therapeutics Completes the Phase I Study of AEG35156/Sorafenib Combination 27
Amgen Announces Phase II Results of Clinical Studies of AMG 479 27
ArQule Announces Commencement of Phase II trial of ARQ 197 by Kyowa Hakko Kirin 28
ArQule Announces Daiichi Sankyo Plans to Move Ahead with Phase III clinical trial of ARQ 197 28
Celgene International Releases the Phase II Trial Data of ISTODAX® in Treatment of PTCL 28
Romidepsin (FK228/depsipeptide) Successfully completes Phase I clinical Trial 28
S*BIO Announces Results of Phase I trial for SB939 for Hematologic Malignancies 29
EntreMed Publishes the Phase II Pre Clinical Results of ENMD-2076 29
Eli Lilly Concludes Phases II trials for LY2181308 in Myeloid Leukaemia 29
Abbott to Present Data On Four Investigational Compounds 29
Can-Fite BioPharma to Commence the Phase I/II Clinical Trial with CF102 30
TetraLogic Announces Inclusion of Pfizer Ventures into the Series C Investors Syndicate 30
DiaTech Oncology Files Patent for MiCK (Microculture Kinetic) Assay 30
Gloucester Pharma Intends to Discuss About New Drug Application for Romidepsin 30
Cleveland BioLabs, Inc. Receives First Patent In the US 30
Daiichi Sankyo Commences Phase II Clinical Trials of CS-1008 31

5. RECENT INDUSTRY ACTIVITY 32
Cephalon to Take Over Gemin X 32
Amarantus BioSciences Enters into Licensing Agreement with Generex Biotechnology 32
Celgene Takes Over Gloucester Pharmaceuticals 32
Sanofi Signs Research and Development Agreement with Ascenta 33
BIOCIUS Life Sciences Collaborates with BlueSky Biotech for Providing Validated Enzymes 33
Ascenta Therapeutics Signs Agreement with Leukemia & Lymphoma Society 33
Ascenta Therapeutics Collaborates with Ascentage Pharma Group
Aposense and Roche Ink Collaboration Agreement
Conatus Takes Over Idun
Cancer Research Technology Enters into Licensing Deal with ValiRx
Scancell Holdings Signs Licensing Agreement with University of Nottingham
D-Pharm Collaborates with Wanbang Biopharmaceuticals
ACEA Biosciences, Roche and Vivo Biosciences Enter into Collaboration
Infinity and Mundipharma Enter Into Global Alliance
Sigma-Aldrich and Highlands Stable Isotope Corporation Enter into an Agreement
EntreMed, Inc. Enters Into Security Purchase Agreement with Group of Strategic Investors
IBA Signs Collaboration Agreement with Aposense
Clinical Data and CombinatoRx Sign Partnership and Licensing Agreement
FASgen and Centocor Ink Research and License Agreement
Graceway Pharmaceuticals Obtains Global Rights for GS 9191 Molecule
Æterna Zentaris Signs an Agreement with Sanofi-Aventis

6. FOCUS ON SELECT PLAYERS
Abbott Laboratories (USA)
AbGenomics International, Inc. (USA)
Aegera Therapeutics, Inc. (Canada)
Amgen, Inc. (USA)
Anavex Life Sciences Corporation (USA)
ApopLogic Pharmaceuticals Inc. (USA)
Ascenta Therapeutics (USA)
ArQule, Inc. (USA)
Bioniche Life Sciences, Inc. (Canada)
Celgene Corporation (USA)
Chroma Therapeutics Ltd (UK)
Cancer Research Technology Ltd. (UK)
EntreMed, Inc. (USA)
EpiCept Corporation (USA)
Exelixis Inc. (USA)
Genextra S.p.A. (Italy)
Genta, Inc. (USA)
Infinity Pharmaceuticals Inc. (USA)
ISIS Pharmaceutical Inc. (USA)
Novartis Ltd. (Switzerland)
Pfizer, Inc. (USA)
Pharmacyclics, Inc. (USA)
*S*BIO Pte Ltd. (Singapore)
Theraptosis SA (France)
TopoTarget A/S (Denmark)
Xigen SA (Switzerland)
Æterna Zentaris GmbH (Germany)

7. GLOBAL MARKET PERSPECTIVE
Table 8: World Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 9: World Historic Review for Apoptosis Modulators in Oncology by Region/Country - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

8. THE UNITED STATES
9. CANADA 61
A. Market Analysis 61
Current & Future Analysis 61
Clinical Trials 61
Recent Industry Activity 61
Key Players 61
B. Market Analytics 62
Table 12: Canadian Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 62
Table 13: Canadian Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 63

10. EUROPE 64
A. Market Analysis 64
Current & Future Analysis 64
Clinical Trials 64
B. Market Analytics 65
Table 14: European Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology by Region/Country - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 65
Table 15: European Historic Review for Apoptosis Modulators in Oncology by Region/Country - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 66
Table 16: European 15-Year Perspective For Apoptosis Modulators in Oncology by Region/Country - Percentage Breakdown of Revenue for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2010 and 2017 (includes corresponding Graph/Chart) 67

10a. FRANCE 68
A. Market Analysis 68
Current & Future Analysis 68
Theraptosis SA - A Key French Player 68
B. Market Analytics 69
Table 17: French Recent Past, Current and Future Analysis
for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 69

Table 18: French Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 70

10b. GERMANY 71
A. Market Analysis 71
   Current & Future Analysis 71
   Æterna Zentaris GmbH - A Key German Player 71
B. Market Analytics 72
Table 19: German Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 72

Table 20: German Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 73

10c. ITALY 74
A. Market Analysis 74
   Current & Future Analysis 74
   Genextra S.p.A. - A Key Italian Player 74
B. Market Analytics 75
Table 21: Italian Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 75

Table 22: Italian Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 76

10d. The UNITED KINGDOM 77
A. Market Analysis 77
   Current & Future Analysis 77
   Recent Industry Activity 77
   Key Players 77
B. Market Analytics 78
Table 23: UK Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 78

Table 24: UK Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 79

10e. SPAIN 80
Market Analysis 80
Table 25: Spanish Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 80

Table 26: Spanish Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 81

10f. REST OF EUROPE 82
A. Market Analysis 82
Current & Future Analysis 82
Key Players 82
B. Market Analytics 83
Table 27: Rest of Europe Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 83

Table 28: Rest of Europe Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 84

11. ASIA-PACIFIC 85
A. Market Analysis 85
Current & Future Analysis 85
Clinical Trials 85
Recent Industry Activity 85
Key Player 87
B. Market Analytics 87
Table 29: Asia-Pacific Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 87

Table 30: Asia-Pacific Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 88

12. LATIN AMERICA 89
A. Market Analysis 89
Current & Future Analysis 89
Recent Industry Activity 89
B. Market Analytics 90
Table 31: Latin America Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 90

Table 32: Latin America Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 91

13. REST OF WORLD 92
A. Market Analysis 92
Current & Future Analysis 92
Clinical Trials 92
Recent Industry Activity 92
B. Market Analytics 93
Table 33: Rest of World Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 93

Table 34: Rest of World Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 94
COMPETITIVE LANDSCAPE

Total Companies Profiled: 114 (including Divisions/Subsidiaries - 123)

-------------------------------------------------------------
Region/Country Players
-------------------------------------------------------------
The United States 74
Canada 4
Japan 4
Europe 30
France 3
Germany 6
The United Kingdom 7
Italy 2
Spain 1
Rest of Europe 11
Asia-Pacific (Excluding Japan) 7
Middle East 4
-------------------------------------------------------------

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1946811/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Apoptosis - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/1946811/
Office Code: SCD2LPL9

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 4200</td>
</tr>
<tr>
<td>1 - 5 Users:</td>
<td>USD 5880</td>
</tr>
<tr>
<td>1 - 10 Users:</td>
<td>USD 7980</td>
</tr>
<tr>
<td>1 - 15 Users:</td>
<td>USD 10080</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: 
Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ______________________
Job Title: _____________________________
Organisation: _________________________
Address: ______________________________
City: _________________________________
Postal / Zip Code: _____________________
Country: ______________________________
Phone Number: _________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World